The 570,000-square-foot Kendall Square tower houses AI-equipped labs built to chase cures for cancer and rare disease.

The deal brings NerveTape, a sutureless nerve-repair device, into Axogen's lineup and is expected to add $34 million in 2027 revenue.

Harvey already counts Ropes & Gray and DraftKings as Boston clients — now it wants a local sales team too.

Beam Therapeutics accuses a former scientist of raiding its lab notebooks before co-founding a rival gene-editing startup developing a treatment for a rare disease.

The Hatfield Apple-1 is one of roughly 75 surviving units and carries a 1978 letter from Steve Jobs himself.

The Swiss drugmaker's new Allston campus grew far beyond its original blueprint, and city leaders showed up to cut the ribbon.

RESI wants to mathematically prove AI models are safe before release, echoing how cryptographers verify secrets.

LabCentral's new soft-landing program hosted its first Loop Week Summit in Kendall Square, no lab lease required.

Sionna Therapeutics is laying off about 27 workers in Waltham after its cystic fibrosis drug flopped in trials.

James Worden's Worden Marine just opened a North Andover innovation hub, betting solar boats can double as floating power plants.

Isembyld is Scholar Rock's first-ever approved drug, targeting muscle loss in spinal muscular atrophy patients nationwide.

A girl's baffling symptoms led her scientist parents to ChatGPT as they searched for answers to her medical mystery.

The AI due-diligence startup is relocating its CEO to Boston as U.S. revenue hits 50% of its total business.